Jim Simons Cassava Sciences Inc Call Options Transaction History
Renaissance Technologies LLC
- $70.6 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SAVA
# of Institutions
131Shares Held
14.2MCall Options Held
963KPut Options Held
866K-
Black Rock Inc. New York, NY3.22MShares$7.47 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$5.03 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny984KShares$2.28 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY790KShares$1.83 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY613KShares$1.42 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $93M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...